Avirmax Inc. Engages at the ARVO Conference on Ocular Gene Therapy
Avirmax's Chief Executive and Scientific Officer, Dr. Shengjiang Shawn Liu, Ph.D., will lead a significant discussion at the upcoming virtual Frontiers in Ocular Gene Therapy Research Conference. This event, organized by the Association for Research in Vision and Ophthalmology (ARVO), focuses on advancing research in ocular gene therapy, a critical area of study for improving vision outcomes.
Exploring AAV's Role in Gene Therapy
The adeno-associated virus (AAV) has become the leading vector for gene therapies thanks to its exceptional features such as stable expression and low immunogenicity. During the session titled "Acceleration of AAV Gene Therapy for Ocular Diseases: Improving Delivery and Quality," Dr. Liu will address the latest innovations in AAV technology. He will specifically present about the recombinant baculovirus-Sf9 Cell (VSaf™AAV) platform used in AAV GMP production for human ocular gene therapy.
Understanding the VSaf™ AAV Platform
The VSaf™ AAV platform has demonstrated the ability to produce AAV vectors at remarkable yields of up to 8x1015 vg/liter using Sf9 cell culture. This technology underpins ABI-110, an AAV vector that introduces a gene for a vascular endothelial growth factor (VEGF) antagonist, which recently received IND approval to begin Phase I/IIa trials, representing a significant leap in gene therapy for ocular diseases.
Clinical Trials and Future Directions
Avirmax's ABI-110 clinical trial is actively enrolling participants across various clinical sites, demonstrating the company's commitment to enhancing patient outcomes in ophthalmic therapy. Avirmax remains at the forefront of developing treatments for conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma.
The Importance of AAV Vector Quality Control
As gene therapies progress, stringent quality control measures for AAV vectors become more critical. During the ARVO conference session, Dr. Liu will also delve into vector quality assurance and viral safety, pillars that ensure the efficacy and safety of these groundbreaking therapies.
About Avirmax Inc.
Avirmax Inc., known for its pioneering AAV engineering technologies, is a clinical-stage company dedicated to developing next-generation gene therapies aimed at various eye conditions, including geographic atrophy and dry AMD. Their innovative Sf9-based AAV manufacturing ensures safe and effective delivery of these therapies, aiming to improve the quality of life for patients suffering from vision impairments.
Contact Information
For further information, please contact June Song, Associate Director for Operations, at info@avirmax.com. You can also reach Avirmax Inc. by calling +1-510-641-0201.
Frequently Asked Questions
What is Avirmax Inc. known for?
Avirmax Inc. specializes in developing advanced gene therapies for various ocular diseases, particularly using AAV technology.
Who will present at the ARVO conference?
Dr. Shengjiang Shawn Liu, the Chief Executive of Avirmax, will lead a session at the ARVO conference.
What is the focus of the AAV technology session?
The session will focus on improving delivery methods and the quality of AAV gene therapies for ocular diseases.
What is the VSaf™ AAV platform?
The VSaf™ AAV platform is a novel technology used by Avirmax to manufacture AAV vectors, enhancing the production process for gene therapies.
How does Avirmax ensure the safety of its therapies?
Avirmax implements rigorous quality control measures and safety testing for its AAV vectors to ensure patient safety and efficacy of treatments.
